tada, excellent post and analysis. Thank you.

That puts some perspective on the possibilities and the framework for what may be considered success in cancer treatments. My understanding is that many cancers are now treated as chronic conditions in which the patient moves through various treatments over time with no cure expected. So it seems that human life is valued at a high level i.e. adding a couple of months or 6 months to a human life is valued by patients, medical people, payers and insurance.

The reason I started thinking about how a "treatment success" would be defined (thus a potential financial success) is that when I was 26 I was diagnosed with 2 types of testicular cancer (chorio and embyonal) and was told I probably had 4 months to live. I had surgery and the 4 months of treatment with vinblastine and bleomycin and then 18 months on some sort of maintainance drug. I survived, had a family and I am healthy in my 60s. So perhaps the surgey worked and the cancer had not metasticised or it had spread but the chemicals cured it? But I lived cancer free.

So, I remember a slide where Don explained how zen3694 was expected to work. Now I am probably wrong on this, but my recall is that zen3694 will turn off production from a specific gene that builds a protein that creates resistance to the effect of enzalutimide hence allowing it to be productive again in killing the cancer cells. Then my simple, non scientific mind begins to wonder if this epigenetic programming by zen3694 could continue forever.

As I recall the patients in the mCRPC trial had an average life expectancy of 3 months. The fact that there is one patient on zen3694 that is alive after 11 months could just be a random fluke i.e. they'd be alive anyway without treatment. The fact that this patient was treated with only zen3694 and no SOC drug then raises very interesting questions about the MOA of zen3694 and it's potential as a stand alone drug for mCRPC.

Hopefully my thoughts are not too muddled.

I remain hopeful yet frustrated by the lack of information. 

GLTA

Toinv